10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2014 | |||
Consolidated Statements of Operations | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 19, 2015) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Revenue | $ 19,615,600 | 23,113,100 | 22,603,400 |
| Cost of sales | 4,932,500 | 4,908,100 | 4,796,500 |
| Research and development | 4,733,600 | 5,531,300 | 5,278,100 |
| Marketing, selling, and administrative | 6,620,800 | 7,125,600 | 7,513,500 |
| Acquired in-process research and development | 200,200 | 57,100 | 0 |
| Asset impairment, restructuring, and other special charges | 468,700 | 120,600 | 281,100 |
| Other-net, (income) expense | 340,500 | 518,900 | 674,000 |
| Cost of sales, operating expenses, and other-net | 16,615,300 | 17,223,800 | 17,195,200 |
| Income before income taxes | 3,000,300 | 5,889,300 | 5,408,200 |
| Income taxes | 609,800 | 1,204,500 | 1,319,600 |
| Net income | 2,390,500 | 4,684,800 | 4,088,600 |
| Weighted-average number of common shares oustanding, including incremental shares | 1,069,932 | 1,080,874 | 1,113,178 |
| Basic earnings per share | 2.23 | 4.33 | 3.67 |
| Weighted-average number of common shares oustanding, including incremental shares and stock options | 1,074,286 | 1,084,766 | 1,117,294 |
| Diluted earnings per share | 2.23 | 4.32 | 3.66 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2014 | |||
Consolidated Statements of Comprehensive Income (Loss) | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 19, 2015) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Net income | $ 2,390,500 | 4,684,800 | 4,088,600 |
| Other comprehensive income (loss) | |||
| Change in foreign currency translation gains (losses) | (961,400) | 36,200 | 160,900 |
| Change in net unrealized gains (losses) on securities | (162,200) | 204,300 | 88,500 |
| Change in defined benefit pension and retiree health benefit plans | 1,327,600 | (2,592,200) | 128,600 |
| Change in effective portion of cash flow hedges | (14,500) | (123,800) | 8,700 |
| Other comprehensive income (loss) before income taxes | (2,465,700) | 2,708,900 | 129,500 |
| Provision for income taxes related to other comprehensive income (loss) items | 476,600 | (914,500) | (68,000) |
| Other comprehensive income (loss) | (1,989,100) | 1,794,400 | 61,500 |
| Comprehensive income | 401,400 | 6,479,200 | 4,150,100 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2014 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 19, 2015) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] | |||
| Net Cash Provided by Operating Activities [Abstract] | |||
| Cash Flows from Operating Activities | |||
| Net income | $ 2,390,500 | 4,684,800 | 4,088,600 |
| Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: | |||
| Depreciation and amortization | 1,379,000 | 1,445,600 | 1,462,200 |
| Change in deferred income taxes | (36,400) | 285,900 | 126,000 |
| Stock-based compensation expense | 156,000 | 144,900 | 141,500 |
| Net realized investment gains | (195,100) | (41,000) | (66,900) |
| Impairment charges, indefinite lived intangibles | 0 | 0 | 205,000 |
| Acquired in-process research and development, net of tax | 130,200 | 37,100 | 0 |
| Income related to termination of the exenatide collaboration with Amylin | 0 | (495,400) | (787,800) |
| Proceeds from terminations of interest rate swaps | 340,700 | 0 | 0 |
| Other non-cash operating activities, net | 241,100 | 66,100 | 187,400 |
| Changes in operating assets and liabilities, net of acquisitions | |||
| Receivables - (increase) decrease | 117,400 | (152,700) | 361,800 |
| Inventories - (increase) decrease | (307,100) | (286,500) | (307,900) |
| Other assets - (increase) decrease | 411,500 | 116,500 | 231,000 |
| Accounts payable and other liabilties-increase (decrease) | (260,700) | (70,300) | (336,100) |
| Net Cash Provided by Operating Activities | 4,367,100 | 5,735,000 | 5,304,800 |
| Net Cash Provided By (Used In) Investing Activities [Abstract] | |||
| Cash Flows from Investing Activities | |||
| Purchases of property and equipment | (1,162,600) | (1,012,100) | (905,400) |
| Disposals of property and equipment | 15,300 | 179,400 | 22,000 |
| Cash restricted for pending acquisition | 5,405,600 | 0 | 0 |
| Proceeds from sales and maturities of short-term investments | 4,054,100 | 3,320,100 | 2,547,500 |
| Purchases of short-term investments | (1,637,800) | (1,531,000) | (2,172,400) |
| Proceeds from sales of noncurrent investments | 11,009,400 | 11,235,000 | 4,355,700 |
| Purchases of noncurrent investments | (9,802,700) | (14,041,900) | (7,618,600) |
| Purchase of product rights | (308,300) | (24,100) | (138,800) |
| Purchases of in-process research and development | (95,000) | (57,100) | 0 |
| Cash paid for acquisitions, net of cash acquired | (551,400) | (43,700) | (199,300) |
| Proceeds from prepayment of revenue-sharing obligation | 0 | 0 | 1,212,100 |
| Other investing activities, net | (24,500) | (97,400) | 64,400 |
| Net Cash Used for Investing Activities | (3,909,100) | (2,072,800) | (2,832,800) |
| Net Cash Used in Financing Activities [Abstract] | |||
| Cash Flows from Financing Activities | |||
| Dividends paid | (2,101,200) | (2,120,700) | (2,187,400) |
| Net change in short-term borrowings | 2,680,600 | 0 | 0 |
| Proceeds from issuance of long-term debt | 992,900 | 0 | 0 |
| Repayments of long-term debt | (1,034,800) | (10,500) | (1,511,100) |
| Purchases of common stock | (800,000) | (1,698,100) | (721,100) |
| Other financing activities, net | 187,400 | 0 | 0 |
| Net Cash Used for Financing Activities | (75,100) | (3,829,300) | (4,419,600) |
| Effect of exchange rate changes on cash and cash equivalents | (341,500) | (21,500) | 43,900 |
| Net increase (decrease) in cash and cash equivalents | 41,400 | (188,600) | (1,903,700) |
| Cash and cash equivalents at beginning of year | 3,830,200 | 4,018,800 | |
| Cash and Cash Equivalents at End of Year | 3,871,600 | 3,830,200 | 4,018,800 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ELI LILLY & CO | ||
Ticker: LLY Fiscal Year: 2014 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2014 10-K (Filed: Feb 19, 2015) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2014 | Dec 31, 2013 | |
| Assets Abstract | ||
| Current Assets | ||
| Cash and cash equivalents | $ 3,871,600 | 3,830,200 |
| Short-term investments | 955,400 | 1,567,100 |
| Accounts receivable, net of allowances of $55.0 (2014) and $62.2 (2013) | 3,234,600 | 3,434,400 |
| Other receivables | 566,700 | 588,400 |
| Inventories | 2,740,000 | 2,928,800 |
| Prepaid expenses and other | 811,500 | 755,800 |
| Total current assets | 12,179,800 | 13,104,700 |
| Other Assets | ||
| Restricted cash | 5,405,600 | 0 |
| Investments | 4,568,900 | 7,624,900 |
| Goodwill | 1,758,100 | 1,516,800 |
| Other intangibles, net | 2,884,200 | 2,814,300 |
| Sundry | 2,417,700 | 2,212,500 |
| Total other assets | 17,034,500 | 14,168,500 |
| Property and equipment, net | 7,963,900 | 7,975,500 |
| Total assets | 37,178,200 | 35,248,700 |
| Liabilities and Shareholders' Equity | ||
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt | 2,688,700 | 1,012,600 |
| Accounts payable | 1,128,100 | 1,119,300 |
| Employee compensation | 759,000 | 943,900 |
| Sales rebates and discounts | 2,068,800 | 1,941,700 |
| Dividends payable | 530,300 | 523,500 |
| Income taxes payable | 93,500 | 254,400 |
| Deferred income taxes | 1,466,500 | 792,800 |
| Other current liabilities | 2,472,600 | 2,328,400 |
| Total current liabilities | 11,207,500 | 8,916,600 |
| Other Liabilities | ||
| Long-term debt | 5,367,700 | 4,200,300 |
| Accrued retirement benefits | 2,562,900 | 1,549,400 |
| Long-term income taxes payable | 998,500 | 1,078,700 |
| Other noncurrent liabilities | 1,653,500 | 1,863,000 |
| Total other liabilities | 10,582,600 | 8,691,400 |
| Shareholders' Equity | ||
| Common stock | 694,600 | 698,500 |
| Additional paid-in capital | 5,292,300 | 5,050,000 |
| Retained earnings | 16,482,700 | 16,992,400 |
| Employee benefit trust | (3,013,200) | (3,013,200) |
| Accumulated other comprehensive loss | (3,991,800) | (2,002,700) |
| Cost of common stock in treasury | (91,400) | (93,600) |
| Total Eli Lilly and Company shareholders' equity | 15,373,200 | 17,631,400 |
| Noncontrolling interests | 14,900 | 9,300 |
| Total equity | 15,388,100 | 17,640,700 |
| Total liabilities and equity | 37,178,200 | 35,248,700 |
| External Links | |
| ELI LILLY & CO (LLY) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |